Continuing Education Activity

Polymorphous light eruption (PMLE) is the most prevalent immunologically mediated photodermatosis and a common cause of recurrent, pruritic eruptions following ultraviolet (UV) exposure. Although typically benign and self-limited, PMLE poses diagnostic and management challenges due to its variable clinical morphology, overlap with other photosensitive dermatoses, and its significant impact on patient quality of life. Inappropriate diagnosis may lead to unnecessary laboratory investigations, unwarranted immunosuppressive therapy, or excessive sun avoidance with downstream psychosocial consequences.

This educational activity provides a comprehensive, evidence-based review of polymorphous light eruption tailored for dermatologists and other clinicians involved in the care of patients with photosensitivity disorders. Participants will review the epidemiology, etiologic hypotheses, immunopathogenesis, histopathologic features, and clinical variants of PMLE. The course highlights the role of the interprofessional healthcare team in improving diagnostic accuracy, patient education, adherence, and long-term outcomes. By reviewing the characteristics, causes, recognition, management, and preventive strategies of polymorphous light eruption, this activity equips healthcare professionals with the knowledge needed to deliver patient-centered, coordinated, and evidence-based care.

Objectives:

• Apply appropriate diagnostic evaluation strategies for polymorphous light eruption and recognize when laboratory testing, biopsy, or photoprovocation is indicated.
• Differentiate polymorphous light eruption from other photosensitive dermatoses based on timing of onset, lesion morphology, distribution, and disease course.
• Select evidence-based preventive and therapeutic interventions for polymorphous light eruption, including photoprotection, photohardening, and systemic prophylaxis.
• Recognize the psychosocial impact and long-term prognosis of polymorphous light eruption and incorporate patient education and interprofessional care into management plans.

Access free multiple choice questions on this topic.

Introduction

Polymorphous light eruption (PMLE), also termed polymorphic light eruption or prurigo aestivalis, is a delayed, abnormal cutaneous reaction to ultraviolet (UV) radiation and is the most common idiopathic photodermatosis worldwide.[1] The disorder is characterized by recurrent pruritic eruptions that appear hours to days after sun exposure, most often during spring or early summer.[2] The polymorphic nature of the disease refers to the wide range of lesion morphologies observed among individuals, although morphology is typically consistent for an individual patient.[3] Recognized variants include juvenile spring eruption, usually affecting the helices of young boys, and PMLE sine eruption, in which patients experience intense pruritus without visible primary lesions.[4] Despite its benign course, PMLE can significantly impair quality of life and lead to social avoidance, anxiety, and occupational limitations.[3]

Etiology

The precise etiology of polymorphous light eruption remains incompletely understood, though current evidence supports a delayed-type hypersensitivity reaction to an endogenous photoantigen generated or modified by UV radiation.[4] In affected individuals, this photoantigen triggers an aberrant immune response rather than the normal UV-induced immunosuppression observed in unaffected skin.[5]

The female predominance suggests a hormonal contribution, with estrogen hypothesized to interfere with UV-mediated immune tolerance.[4] Genetic susceptibility is supported by familial clustering and twin studies, consistent with a polygenic inheritance pattern rather than a monogenic disorder.[2] Environmental factors, including latitude, altitude, and cumulative UV exposure, further modulate disease expression.[1]

Epidemiology

The prevalence of PMLE varies significantly across geographic regions and latitudes, with the highest rates reported in Northern Europe.[2] Large population-based studies estimate prevalence rates of approximately 10% to 20% in Northern European populations.[1] Lower prevalence has been reported in Australasia and equatorial regions, reflecting differences in UV exposure patterns and adaptive photohardening.[2]

Polymorphous light eruption affects all Fitzpatrick skin phototypes but occurs more frequently in lighter skin types.[4] Approximately three-quarters of cases begin in women aged 20 to 40 years, although onset may occur in childhood or later adulthood.[3] Increased prevalence has been reported at higher altitudes, likely due to greater UV intensity.[1]

Pathophysiology

Polymorphous light eruption is characterized by defective UV-induced immunosuppression in the skin.[5]. Ultraviolet exposure leads to the formation of a photoantigen that activates cutaneous immune responses rather than inducing tolerance.[6]. Lesional skin demonstrates a predominance of CD4+ T lymphocytes and increased expression of proinflammatory cytokines.[5]

Regulatory T-cell dysfunction, altered plasmacytoid dendritic cell activity, and changes in antimicrobial peptide expression contribute to immune dysregulation.[7] Photohardening is associated with restoration of immune tolerance and changes in epidermal immune cell populations.[6] Emerging data suggest that the cutaneous microbiome may modulate UV-induced immune responses in PMLE.[8]

Histopathology

Histopathologic findings in polymorphous light eruption are nonspecific but supportive when correlated with clinical findings.[9] Early lesions demonstrate papillary dermal edema with a superficial and deep perivascular lymphocytic infiltrate.[9] Periadnexal inflammation is common, and endothelial swelling may be present without evidence of vasculitis.[10] Spongiosis, vesicle formation, and focal basal vacuolar alteration may be observed depending on clinical morphology.[11] Immunophenotyping demonstrates a predominance of CD4+ T cells, and findings from direct immunofluorescence studies are negative, supporting differentiation from cutaneous lupus erythematosus.[7][10][12]

Toxicokinetics

Ultraviolet A (UVA) is the usual part of the electromagnetic spectrum that provokes polymorphous light eruption (75%-90% of cases). However, in some patients, it can be triggered by ultraviolet B (UVB) or visible light. Exposure may be to sunlight or from artificial or medical sources of UV radiation.[13]

History and Physical

A detailed history and physical examination are central to the diagnosis of polymorphous light eruption.[3] Patients typically report the onset of symptoms after the first significant sun exposure of the year, often following outdoor activities during spring or early summer.[2] A symptom-free winter followed by abrupt recurrence with sun exposure is highly characteristic.[4]

Latency between UV exposure and eruption is a critical diagnostic clue, with lesions developing hours to days after exposure.[3] Patients frequently describe intense pruritus, burning, or stinging sensations that may precede visible lesions.[3] Distribution favors newly exposed areas, including the décolletage (neck and upper chest), extensor forearms, dorsal hands, lower extremities, and feet. (See Image. Polymorphic Light Eruption.)[2]

The face is typically spared, likely due to chronic exposure and photohardening.[4] Morphology varies between individuals but is consistent within patients and includes papules, plaques, vesicles, lichenoid lesions, and prurigo-like nodules (See Image. Papular Polymorphic Light Eruption.)[3][14][15][16] Lesions resolve without scarring if UV exposure ceases, although repeated exposure may prolong the disease until photohardening occurs.[2][17]

Evaluation

Diagnosis of polymorphous light eruption is primarily clinical and based on characteristic history and examination findings.[18] Laboratory evaluation is typically unnecessary unless features are atypical or suggest systemic disease.[4] However, results from a study of 94 patients with PMLE reported that 14 eventually developed an autoimmune disease, including 2 who developed systemic lupus erythematosus; another 13 developed thyroid disease, although it is unclear whether polymorphous light eruption predisposes patients to these conditions.[19] Skin biopsy may be performed to exclude other photodermatoses; however, it yields nonspecific findings.[20]

Antinuclear antibodies may be detected at low titers but are not diagnostic of systemic lupus erythematosus in the absence of clinical features.[18] Porphyrin testing should be performed when porphyria is suspected, and results are normal in PMLE.[18] Photoprovocation testing may reproduce lesions but has a false-negative rate of up to 40% and is reserved for specialized centers.[21][22]

Treatment / Management

Management of polymorphous light eruption centers on preventing UV–induced flares and inducing photohardening, while minimizing disease-related morbidity.[2] Patient education regarding the pathogenesis of PMLE and the rationale for preventive strategies is fundamental to successful management.[3] Photoprotection represents first-line therapy and includes broad-spectrum sunscreens with high UVA protection, sun-protective clothing, and behavioral modifications such as avoiding midday sun exposure.[4] Patients should be counseled that UVA radiation penetrates window glass and that standard sunscreens may provide incomplete UVA protection, necessitating physical barriers and behavioral strategies.[2] 

Photohardening through controlled ultraviolet exposure is a cornerstone of preventive therapy.[23] Prophylactic narrowband UVB or psoralen plus UVA therapy initiated in late winter or early spring reduces the incidence and severity of PMLE flares during subsequent natural sun exposure.[24] Narrowband UVB is often preferred due to its favorable safety profile and efficacy in inducing photohardening.[23] Gradual increases in UV exposure (with appropriate sun protection) may reduce the intensity and delay symptom onset.

Systemic pharmacologic prophylaxis may be considered in patients with predictable exposures or severe disease.[25]. Hydroxychloroquine has demonstrated efficacy in randomized controlled trial findings and is typically initiated several weeks prior to anticipated sun exposure.[25] Antioxidant and oral photoprotective agents, including Polypodium leucotomos extract and nicotinamide, have emerging evidence of benefit in reducing UV-induced erythema and DNA damage.[26][27][28]

Topical corticosteroids are useful for symptomatic management during acute flares and may reduce pruritus and duration of lesions.[3] Short courses of systemic corticosteroids may be considered in exceptional circumstances, such as unavoidable, intense UV exposure, although routine use is discouraged due to limited evidence and potential adverse effects.[4] Monoclonal antibodies and Janus kinase inhibitors may have an emerging role in the treatment of PMLE.[29]

Differential Diagnosis

The differential diagnosis of polymorphous light eruption is broad and includes other photosensitive and photoaggravated dermatoses that may present with overlapping clinical features.[4] Accurate differentiation is essential to avoid unnecessary investigations or inappropriate treatment. Cutaneous lupus erythematosus represents the most important differential diagnosis because it may present with photosensitive eruptions and systemic implications.[7] Unlike PMLE, lupus-associated photosensitivity often produces more persistent lesions, may involve the face, and frequently demonstrates positive direct immunofluorescence findings and serologic abnormalities.[18]

Solar urticaria is characterized by an immediate onset within minutes of UV exposure and rapid resolution upon cessation of exposure, in contrast to the delayed onset observed in PMLE.[21][30] Chronic actinic dermatitis presents with persistent eczematous plaques, marked photosensitivity, and a chronic course that does not demonstrate seasonal photohardening.[2] Other conditions to consider include photoaggravated atopic dermatitis, drug-induced photosensitivity, porphyria cutanea tarda, and erythropoietic protoporphyria, each of which can be distinguished based on clinical history, morphology, and targeted laboratory evaluation.[18]

Prognosis

The prognosis of polymorphous light eruption is excellent, with no associated increase in mortality or systemic disease risk.[3] Many patients experience gradual improvement in disease severity and frequency over time, particularly with repeated seasonal exposure and photohardening.[2]

Longitudinal studies suggest that a substantial proportion of patients experience partial or complete remission later in adulthood.[3] Despite this favorable natural history, disease burden may remain significant during active years, underscoring the importance of preventive strategies and patient education.[4]

Complications

Polymorphous light eruption is generally uncomplicated from a medical standpoint.[2] However, recurrent disease may result in substantial psychosocial morbidity, including anxiety, depression, social withdrawal, and occupational limitations related to sun avoidance.[3] Excessive photoprotection and sun avoidance may contribute to vitamin D deficiency, which has been documented in patients with photosensitive disorders.[31] Iatrogenic complications may also arise from long-term use of systemic therapies, emphasizing the importance of individualized risk-benefit assessment.[25]

Deterrence and Patient Education

Deterrence of polymorphous light eruption relies heavily on patient education and anticipatory guidance.[3] Patients should be counseled regarding the seasonal nature of the disease, expected improvement with photohardening, and realistic expectations for preventive strategies.[4] Education on proper sunscreen selection, application technique, and reapplication frequency is essential to maximize efficacy.[2] Counseling should also address lifestyle modifications, travel planning, and, when appropriate, the importance of gradual sun exposure.[8]

Enhancing Healthcare Team Outcomes

Optimal management of polymorphous light eruption requires coordinated interprofessional care.[8] Dermatologists play a central role in diagnosis, treatment planning, and patient education, while primary care clinicians reinforce preventive strategies and monitor long-term outcomes.[4] Nurses support patient education and adherence to phototherapy regimens, pharmacists counsel on systemic therapies and phototoxic risks, and mental health professionals address psychosocial sequelae associated with chronic disease.[3] Effective communication, shared decision-making, and coordinated care improve patient satisfaction, safety, and quality of life in individuals with polymorphous light eruption.[5]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Rhodes LE, Bock M, Janssens AS, Ling TC, Anastasopoulou L, Antoniou C, Aubin F, Bruckner T, Faivre B, Gibbs NK, Jansen C, Pavel S, Stratigos AJ, de Gruijl FR, Diepgen TL. Polymorphic light eruption occurs in 18% of Europeans and does not show higher prevalence with increasing latitude: multicenter survey of 6,895 individuals residing from the Mediterranean to Scandinavia. J Invest Dermatol. 2010 Feb;130(2):626-8. [PubMed: 19693026]

2.

Pao C, Norris PG, Corbett M, Hawk JL. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol. 1994 Jan;130(1):62-4. [PubMed: 8305319]

3.

Ling TC, Richards HL, Janssens AS, Anastassopoulou L, Antoniou C, Aubin F, Diepgen TL, Fazakerley R, de Gruijl FR, Jansen CT, Pavel S, Smedley A, Stratigos AJ, Webb AR, Gibbs NK, Rhodes LE. Seasonal and latitudinal impact of polymorphic light eruption on quality of life. J Invest Dermatol. 2006 Jul;126(7):1648-51. [PubMed: 16614724]

4.

Aubin F. Why is polymorphous light eruption so common in young women? Arch Dermatol Res. 2004 Oct;296(5):240-1. [PubMed: 15349790]

5.

Schweintzger N, Gruber-Wackernagel A, Reginato E, Bambach I, Quehenberger F, Byrne SN, Wolf P. Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening. Br J Dermatol. 2015 Aug;173(2):519-26. [PMC free article: PMC4564948] [PubMed: 26032202]

6.

Wolf P, Gruber-Wackernagel A, Bambach I, Schmidbauer U, Mayer G, Absenger M, Fröhlich E, Byrne SN. Photohardening of polymorphic light eruption patients decreases baseline epidermal Langerhans cell density while increasing mast cell numbers in the papillary dermis. Exp Dermatol. 2014 Jun;23(6):428-30. [PubMed: 24758562]

7.

Wackernagel A, Massone C, Hoefler G, Steinbauer E, Kerl H, Wolf P. Plasmacytoid dendritic cells are absent in skin lesions of polymorphic light eruption. Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):24-8. [PubMed: 17254032]

8.

Burfield L, Rutter KJ, Thompson B, Marjanovic EJ, Neale RE, Rhodes LE. Systematic review of the prevalence and incidence of the photodermatoses with meta-analysis of the prevalence of polymorphic light eruption. J Eur Acad Dermatol Venereol. 2023 Mar;37(3):511-520. [PubMed: 36433668]

9.

Hölzle E, Plewig G, von Kries R, Lehmann P. Polymorphous light eruption. J Invest Dermatol. 1987 Mar;88(3 Suppl):32s-38s. [PubMed: 3819473]

10.

Rossi MT, Arisi M, Lonardi S, Lorenzi L, Ungari M, Serana F, Fusano M, Moggio E, Calzavara-Pinton PG, Venturini M. Cutaneous infiltration of plasmacytoid dendritic cells and T regulatory cells in skin lesions of polymorphic light eruption. J Eur Acad Dermatol Venereol. 2018 Jun;32(6):985-991. [PubMed: 29430717]

11.

Lane PR, Murphy F, Hogan DJ, Hull PR, Burgdorf WH. Histopathology of actinic prurigo. Am J Dermatopathol. 1993 Aug;15(4):326-31. [PubMed: 8214390]

12.

Karagun E, Gamsizkan M, Buyucek S, Coskun S. CD123 immunoexpression in cutaneous lupus erythematosus, polymorphous light eruption, pityriasis rosea, and mycosis fungoides. Postepy Dermatol Alergol. 2021 Dec;38(6):994-1000. [PMC free article: PMC8802971] [PubMed: 35126006]

13.

Gruber-Wackernagel A, Hofer A, Legat F, Wolf P. Frequency of occurrence of polymorphic light eruption in patients treated with photohardening and patients treated with phototherapy for other diseases. Photodermatol Photoimmunol Photomed. 2019 Mar;35(2):100-105. [PMC free article: PMC7379702] [PubMed: 30267642]

14.

Kurz B, Arndt S, Unger P, Ivanova I, Berneburg M, Hellerbrand C, Karrer S. Association of polymorphous light eruption with NOD-2 and TLR-5 gene polymorphisms. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2172-2180. [PubMed: 35748133]

15.

Karthikeyan K, Aishwarya M. Polymorphous Light Eruption- An Indian Scenario. Indian Dermatol Online J. 2021 Mar-Apr;12(2):211-219. [PMC free article: PMC8088173] [PubMed: 33959517]

16.

Sharma VK, Sahni K. Photodermatoses in the Pigmented Skin. Adv Exp Med Biol. 2017;996:111-122. [PubMed: 29124695]

17.

Patra V, Strobl J, Atzmüller D, Reininger B, Kleissl L, Gruber-Wackernagel A, Nicolas JF, Stary G, Vocanson M, Wolf P. Accumulation of Cytotoxic Skin Resident Memory T Cells and Increased Expression of IL-15 in Lesional Skin of Polymorphic Light Eruption. Front Med (Lausanne). 2022;9:908047. [PMC free article: PMC9226321] [PubMed: 35755042]

18.

Das S, Lloyd JJ, Walshaw D, Farr PM. Provocation testing in polymorphic light eruption using fluorescent ultraviolet (UV) A and UVB lamps. Br J Dermatol. 2004 Nov;151(5):1066-70. [PubMed: 15541086]

19.

Hasan T, Ranki A, Jansen CT, Karvonen J. Disease associations in polymorphous light eruption. A long-term follow-up study of 94 patients. Arch Dermatol. 1998 Sep;134(9):1081-5. [PubMed: 9762018]

20.

Matekovits A, Dalamaga M, Stratigos A, Katsambas A, Antoniou C. Polymorphous light eruption under the Mediterranean sun: a clinico-epidemiological and photobiological study. Eur J Dermatol. 2016 Jun 01;26(3):304-6. [PubMed: 27020379]

21.

van de Pas CB, Hawk JL, Young AR, Walker SL. An optimal method for experimental provocation of polymorphic light eruption. Arch Dermatol. 2004 Mar;140(3):286-92. [PubMed: 15023772]

22.

Chiam LY, Chong WS. Pinpoint papular polymorphous light eruption in Asian skin: a variant in darker-skinned individuals. Photodermatol Photoimmunol Photomed. 2009 Apr;25(2):71-4. [PubMed: 19292781]

23.

Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol. 1993 Dec;129(6):708-12. [PubMed: 8286256]

24.

Murphy GM, Logan RA, Lovell CR, Morris RW, Hawk JL, Magnus IA. Prophylactic PUVA and UVB therapy in polymorphic light eruption--a controlled trial. Br J Dermatol. 1987 Apr;116(4):531-8. [PubMed: 3555596]

25.

Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol. 1987 Mar;116(3):379-86. [PubMed: 3552020]

26.

Faisal A, Philipsen PA, Lerche CM, Douki T, Laursen FSW, Granborg JR, Bjerring P, Haedersdal M, Wiegell SR. Changes in ultraviolet B radiation-induced DNA damage and erythema after oral nicotinamide and polypodium leucotomos in healthy volunteers: an intraindividual controlled trial. Photochem Photobiol Sci. 2025 Nov;24(11):1951-1958. [PubMed: 41182568]

27.

Tanew A, Radakovic S, Gonzalez S, Venturini M, Calzavara-Pinton P. Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. J Am Acad Dermatol. 2012 Jan;66(1):58-62. [PubMed: 21696853]

28.

Caccialanza M, Recalcati S, Piccinno R. Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses. G Ital Dermatol Venereol. 2011 Apr;146(2):85-7. [PubMed: 21505393]

29.

Alawadhi JF, Ayer J. Efficacy of monoclonal antibodies and Janus kinase inhibitors in the treatment of idiopathic photosensitive skin disorders: a systematic review. Clin Exp Dermatol. 2026 Mar 26;51(4):548-554. [PubMed: 41192435]

30.

Reolid A, Muñoz-Aceituno E, Rodríguez-Jiménez P, de Argila D. Delayed-onset Solar Urticaria Coexisting With Spontaneous Chronic Urticaria and Polymorphic Light Eruption. Actas Dermosifiliogr. 2022 Nov-Dec;113(10):978-979. [PubMed: 35835177]

31.

Gruber-Wackernagel A, Obermayer-Pietsch B, Byrne SN, Wolf P. Patients with polymorphic light eruption have decreased serum levels of 25-hydroxyvitamin-D3 that increase upon 311 nm UVB photohardening. Photochem Photobiol Sci. 2012 Dec;11(12):1831-6. [PubMed: 22952008]

Disclosure: Nishad Sathe declares no relevant financial relationships with ineligible companies.

Disclosure: Michael Ramsey declares no relevant financial relationships with ineligible companies.